Clinical Trial Update: Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial assessed neoadjuvant Lu-PSMA radioligand therapy in combination with ipilimumab for men with very high-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)
• Yervoy (ipilimumab)

Snippet

Sponsor: University Hospital, Essen | Conditions: Very High Risk Prostate Carcinoma | Phase 1, Phase 2 | Status: TERMINATED